Nabriva Therapeutics to present its data at IDWeek 2021

0

DUBLIN, Ireland and FORT WASHINGTON, Pa., September 24, 2021 (GLOBE NEWSWIRE) – Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the presentation of the data at the Infectious Disease Society of America (IDSA) IDWeek ™ 2021 which will run virtually from September 29 to October 3, 2021.

Nabriva, with his collaborators, will present a poster presentation on the in vitro activity of lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis. XENLETA® (lefamulin) is a first-class pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CAP).

PRESENTATION:

Session title: Respiratory infections – Bacterial
Title of the poster: “In vitro activity of Lefamulin against Staphylococcus aureus isolated from the lower respiratory tract of children with cystic fibrosis’
Session ID: 1058520
Speaker: Dr Helio S. Sader, MD, Ph.D., FIDSA (Senior Director, JMI Laboratories)

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics Receives U.S. Food and Drug Administration Approval For XENLETA® (injection of lfamulin, lfamulin tablets), the first systemic antibiotic based on pleuromutilin for community bacterial pneumonia (CAP). Nabriva Therapeutics is also developing CONTEPO ™ (fosfomycin) for injection, a first-class epoxy antibiotic with potential for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, NJ, USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and some of its territories.

Forward-looking statements

All statements in this press release regarding Nabriva Therapeutics ‘future expectations, plans and prospects, including, but not limited to, statements about Nabriva Therapeutics’ ability to promote XENLETA and SIVEXTRO, to stimulate growth in demand for prescriptions and drive sales growth, the potential patient benefits of SIVEXTRO and XENLETA, the market opportunity for SIVEXTRO and XENLETA, the availability of SIVEXTRO through leading specialist wholesalers in United States, the impact on Nabriva Therapeutics’ reported revenues from anticipated sales of SIVEXTRO, its liquidity sufficiency and other statements containing the words “anticipate”, “believe”, “estimate”, “expect” to ”,“ intend ”,“ may ”,“,. “” Will “,” would “,” could “,” should “,” continue “and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those shown by these forward-looking statements due to various important factors, including: the ability of Nabriva Therapeutics to comply with its obligations under its loan agreement with Hercules, the ability of Nabriva Therapeutics to maintain the terms of the distribution agreement for exclusively distribute and promote SIVEXTRO, including its ability to maintain sufficient commercial infrastructure to promote and distribute SIVEXTRO, the extent of business disruptions resulting from the infection causing the COVID-19 outbreak or crises similar public health, the ability to retain and hire key personnel, the availability of adequate additional funding at c conditions are acceptable or not at all and other important factors as set out in Nabriva Therapeutics’ annual and quarterly reports and other documents filed with the SEC. In addition, the forward-looking statements included in this press release represent the views of Nabriva Therapeutics as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments could change its point of view. However, although Nabriva Therapeutics may choose to update these forward-looking statements at some time in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be taken as representing the views of Nabriva Therapeutics as of a date subsequent to the date of this press release.

CONTACTS:

For investors

Kim anderson
Nabriva Therapeutics plc
[email protected]

For the media

Andrea Greif
Ogilvy
[email protected]
914-772-3027


Source link

Leave A Reply

Your email address will not be published.